CD138, also known as syndecan-1, is a surface molecule found on plasma cells that serves as one of the most reliable markers pathologists use to identify these antibody-producing cells in tissue samples. Its significance extends well beyond simple identification, though. CD138 actively participates in keeping plasma cells alive, helps them communicate with their surrounding tissue, and, when things go wrong, contributes to the progression of cancers like multiple myeloma. Understanding what CD138 does on plasma cells, how its expression is controlled, and where it shows up in diagnostic work reveals a molecule that sits at the intersection of normal immunity, reproductive medicine, and cancer biology.
What CD138 Actually Does on a Plasma Cell
Plasma cells are the immune system’s antibody factories. Once a B cell encounters a threat and fully matures into a plasma cell, it begins mass-producing antibodies. CD138 is a protein that sits on the outer surface of these cells and carries chains of a sugar-like molecule called heparan sulfate. Those sugar chains act like molecular Velcro, grabbing onto growth factors, survival signals, and structural proteins in the surrounding tissue. This makes CD138 far more than a passive label. It is essential for maintaining normal cell shape, relaying signals from the environment into the cell interior, and interacting with a wide range of proteins both inside and outside the cell.1PubMed Central. Targeting syndecan-1: new opportunities in cancer therapy
In the bone marrow, where long-lived plasma cells take up residence, CD138 functions as a master regulator of the conversation between the plasma cell and its microenvironment. It co-opts specific growth and survival factors from the bone marrow niche, channeling them to the cell in a way that keeps the plasma cell alive and productive for months or even years.2PubMed Central. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis It also binds to fibronectin, a large structural protein in the bone marrow’s connective tissue, physically tethering the plasma cell in place. That tethering appears to confer a survival advantage: when researchers blocked fibronectin in laboratory experiments on human antibody-secreting cells, survival dropped.3Nature Communications. Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion
How CD138 Gives Mature Plasma Cells a Survival Edge
Not all antibody-secreting cells express the same amount of CD138. Newer, freshly formed cells tend to have less of it, while fully mature plasma cells have high levels. This difference turns out to be functionally important. Higher CD138 surface expression increases the amount of heparan sulfate on the cell, which in turn captures more pro-survival cytokines from the surrounding tissue. The result is a built-in selection mechanism: cells with more CD138 survive better in the bone marrow, outcompeting less mature cells for limited survival signals.4PubMed Central. CD138 mediates selection of mature plasma cells by regulating their survival This is why long-lived plasma cells, the ones responsible for maintaining antibody levels years after a vaccination or infection, are strongly CD138-positive. The molecule is not just a convenient stain for pathologists; it is part of the reason these cells persist.
The Transcription Factors That Switch CD138 On
A plasma cell does not simply appear with CD138 already in place. The transformation from an activated B cell to a mature plasma cell is driven by a cascade of gene-regulating proteins. Two of the most important are IRF4 and BLIMP1 (encoded by the gene PRDM1). Research into how these factors work together has revealed a carefully ordered sequence. IRF4 acts first, silencing the gene programs that define an activated B cell, shutting down proliferation signals and the B cell receptor. It also switches on PRDM1, triggering production of BLIMP1. BLIMP1 then extinguishes any remaining activated B cell survival genes and, together with IRF4, turns on the machinery the cell needs to become a protein-secreting powerhouse, including the endoplasmic reticulum and unfolded protein response pathways that handle antibody production.5eLife. Regulatory logic and motif lexicon of IRF4 and BLIMP1 in human plasma cell differentiation CD138 expression rises as part of this maturation program. When the process goes wrong, as it does in certain lymphomas or immune deficiencies, plasma cell formation stalls, and CD138 expression may be absent or abnormal.
Diagnosing Multiple Myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow, and CD138 is central to its diagnosis. When a pathologist examines a bone marrow biopsy from someone suspected of having myeloma, CD138 immunohistochemistry (a staining technique that highlights cells expressing the protein) is one of the first tools they reach for. It allows excellent assessment of both the number and the distribution pattern of plasma cells in the tissue.6PubMed Central. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry
One reason CD138 staining is so valuable is that the traditional method of counting plasma cells on an aspirate smear can be unreliable. A study comparing different counting methods in 79 bone marrow samples from myeloma patients found relatively poor agreement between aspirate smear estimates and CD138-stained biopsy sections. CD138 staining consistently produced the highest agreement between different observers, and computer-assisted image analysis confirmed its accuracy. Beyond simply counting cells, CD138 staining can reveal patterns of infiltration, like interstitial spreading or dense clusters, that point toward a neoplastic process even when the overall plasma cell percentage is not dramatically elevated.6PubMed Central. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry
That said, CD138 is not a perfect cancer-specific marker. More than 95% of myeloma cells stain positive for it in most biopsies, but so do normal plasma cells.7Modern Pathology. Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions CD138 alone cannot distinguish a cancerous plasma cell from a healthy one.8PubMed Central. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells This is why pathologists and hematologists use it in panels alongside other markers. In flow cytometry, for instance, a common approach combines CD138 with CD38, CD56, CD19, and CD45. Normal plasma cells tend to be CD19-positive and CD56-negative, while myeloma cells frequently flip that pattern. The combination lets clinicians separate the two populations in a way that CD138 staining by itself cannot.9PubMed Central. Immunophenotype of Normal and Myelomatous Plasma-Cell Subsets
Soluble CD138 as a Prognostic Signal
CD138 does not always stay attached to the cell surface. It can be cleaved off, or “shed,” into the surrounding fluid. In myeloma patients, this shed form, called soluble CD138 (sCD138), is measurable in the blood. Its levels carry prognostic weight: patients with high sCD138 at diagnosis (above roughly 500 ng/mL) had a worse prognosis, even when some of them responded well to initial chemotherapy.10PubMed. The significance of soluble CD138 in diagnosis of monoclonal gammopathies
The shedding itself is not a passive event. In myeloma, an enzyme called heparanase trims the heparan sulfate chains on CD138, after which another enzyme clips the protein free from the cell surface. The shed fragment does not simply float away inertly. It carries growth factors like VEGF with it, and these complexes anchor into the surrounding tissue matrix, where they activate receptors on nearby blood vessel cells. The result is new blood vessel formation, or angiogenesis, which feeds the growing tumor.11PubMed Central. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis Researchers have identified the exact binding site on the shed CD138 fragment that couples two receptors together on endothelial cells, triggering them to become invasive and form tubes. Small peptides called synstatins, designed to block that binding site, can inhibit both invasion and tube formation in laboratory models.12PubMed Central. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
CD138 Staining in Chronic Endometritis
One of the more surprising diagnostic roles for CD138 is in reproductive medicine. Chronic endometritis is a subtle, low-grade inflammation of the uterine lining that can interfere with embryo implantation and is a recognized cause of recurrent implantation failure in fertility treatment. Unlike acute endometritis, which causes obvious symptoms, the chronic form is often clinically silent. Its hallmark on biopsy is the presence of plasma cells in the endometrial tissue, where they do not normally belong in significant numbers.13PubMed Central. The role of endometrial staining for CD138 as a marker of chronic endometritis in predicting live birth
Standard tissue staining can make plasma cells difficult to spot among the normal inflammatory cells of the endometrium. CD138 immunohistochemistry solves this by lighting up plasma cells specifically, making them far easier to count. It has become the main diagnostic criterion for chronic endometritis in the context of recurrent implantation failure.14PubMed. Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome
A practical challenge, though, is that there is no universally agreed-upon number of CD138-positive cells that defines a positive diagnosis. One study compared different thresholds and found that an average of five or more CD138-positive (and CD38-positive) cells per high-power microscope field in the most affected areas gave the best agreement with direct visual inspection of the uterus by hysteroscopy, though the agreement was only moderate. A slightly lower threshold of four cells per field proved more useful for tracking whether antibiotic treatment had cleared the condition, with about 79% of treated patients converting to negative at that cutoff.15Clinical and Experimental Obstetrics & Gynecology. Evaluation of CD38 and CD138 as Diagnostic Markers in the Pathologic Diagnosis of Chronic Endometritis The lack of a firm universal standard means that a diagnosis of chronic endometritis can vary between labs, something worth knowing if you are navigating fertility treatment and receive this diagnosis.
CD138 in Solid Tumors and Epithelial-Mesenchymal Transition
CD138 is not exclusive to plasma cells. Epithelial cells throughout the body, including those lining the skin, gut, and lungs, also express it. In those settings, it helps maintain cell-to-cell adhesion and tissue architecture. This is where its relevance to carcinomas comes in. As solid tumors become more aggressive, CD138 expression on the cancer cells frequently drops. This decline tends to parallel increasing tumor grade, invasiveness, and dedifferentiation, the process where cancer cells lose their specialized identity and become more primitive and mobile.16PubMed Central. Syndecan-1 (CD138), Carcinomas and EMT The loss of CD138 can accompany the loss of cadherin-mediated adhesion, a key step in what is called epithelial-mesenchymal transition. In some contexts, then, low or absent CD138 expression on a carcinoma may signal a more aggressive phenotype, which is the opposite of its significance in myeloma, where high expression defines the disease.
Targeting CD138 with Drugs
Because CD138 is so heavily expressed on myeloma cells, it has attracted attention as a target for directed therapy. The most advanced approach in clinical testing has been indatuximab ravtansine (also known as BT062), an antibody-drug conjugate. This is essentially an antibody that recognizes CD138 and carries a cell-killing toxin as cargo. When it locks onto CD138 on a myeloma cell, the whole complex gets internalized, and the toxin is released inside the cell.
In early clinical trials for patients with relapsed or treatment-resistant myeloma, the drug showed a manageable safety profile. The maximum tolerated dose was established at 160 mg/m², with mouth sores (mucositis) as the main dose-limiting side effect. Most adverse events were mild. Among heavily pretreated patients, disease stabilization was the most common outcome, with some patients showing meaningful reductions in their disease markers.17Blood. BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma In monotherapy, over three-quarters of heavily pretreated patients achieved stable disease or better, and about 15% had measurable partial or minor responses. Median overall survival was roughly 27 months, which is notable for a population that had run through multiple prior treatment lines.18PubMed. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
When combined with standard backbone agents like lenalidomide or pomalidomide plus dexamethasone, results improved substantially. About 72% of patients receiving the lenalidomide combination and about 71% of those on the pomalidomide combination achieved an objective response.19The Lancet Haematology. Indatuximab ravtansine in combination with lenalidomide or pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (ME1st): a phase 1/2a study These numbers are encouraging, though the combination regimens also came with higher rates of blood count suppression. Researchers are also exploring CD138-directed CAR-T cells, though early reports suggest that the same CD138 shedding that makes sCD138 a blood biomarker may blunt the efficacy of this approach by flooding the environment with decoy targets.
CD138 Beyond Myeloma and Endometritis
CD138 shows up in the diagnostic workup of other plasma cell disorders as well. Solitary plasmacytoma, a single tumor mass of plasma cells that has not yet spread to become full-blown myeloma, is routinely confirmed by showing that the tumor cells stain positive for CD138. In one reported case of a plasmacytoma arising on the palate, CD138 positivity, along with light-chain restriction, was a key element in establishing the diagnosis and ruling out other tumors that can look similar under the microscope.20Cancer Diagnosis & Prognosis. Palatal Solitary Plansmacytoma: A Case Report on Post-radiotherapy Challenges
Beyond malignancy, CD138-positive plasma cells are relevant in autoimmune disease. In conditions like lupus and Sjögren’s disease, self-reactive plasma cells continuously churn out autoantibodies that attack the body’s own tissues. Because these cells can be long-lived and resistant to standard immunosuppression, they represent a stubborn treatment challenge. CD138 helps identify them in tissue biopsies and is part of the rationale for newer therapies aimed specifically at depleting the plasma cell compartment, rather than broadly suppressing the immune system.
The molecule also plays a role in infectious disease biology. Because of its heparan sulfate chains, CD138 can serve as an attachment point for certain pathogens, facilitating microbial entry into cells. It modulates leukocyte recruitment to infection sites and influences the tissue remodeling that occurs during wound healing and inflammation.21PubMed Central. Molecular functions of syndecan-1 in disease These functions are not limited to plasma cells, since CD138 on epithelial surfaces mediates many of these interactions.
Emerging Markers and the Limits of CD138
For all its utility, CD138 has some well-known weaknesses as a marker. It is not specific to plasma cells, appearing on epithelial cells throughout the body. It can be shed from the cell surface during sample processing, which means flow cytometry panels sometimes undercount CD138-positive cells if specimens are not handled quickly. And in myeloma specifically, occasional cases show substantial populations of CD138-negative tumor cells, complicating diagnosis.7Modern Pathology. Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions
Researchers have been looking for complementary or alternative markers, and one intriguing candidate is CD102 (also called ICAM-2). Studies in non-human primates initially identified CD102 as a marker that was restricted almost exclusively to long-lived plasma cells in the bone marrow. Follow-up work showed that nearly all long-lived plasma cells in mice also expressed CD102, and human bone marrow confirmed the pattern as well, with CD102-positive and CD31-positive sorted cells containing the antibody-secreting population. The catch is that in humans and mice, CD102 expression is not as tightly restricted to plasma cells as it is in non-human primates, showing up on other bone marrow cells too.22Communications Biology. Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells Still, CD102 could prove useful in combination with CD138, particularly for research aimed at understanding why some plasma cells persist for decades while others fade after weeks. The science of plasma cell identity is still evolving, and CD138, though indispensable today, is likely to become one marker among several in an increasingly refined toolkit.